Announced
Synopsis
Athenex, a biopharmaceutical company, agreed to acquire Kuur Therapeutics, developer of cell immunotherapies for the treatment of solid and hematological malignancies, from Schroder, a closed-ended investment company, for $185m. “Kuur’s innovative technology, combined with our TCR program, could propel us into a leadership position in cell therapy. This platform also has the potential to provide synergies with other assets in our pipeline,” Johnson Lau, Athenex CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.